• 专利标题:   Graphene nanomaterial useful in pharmaceutical composition for treating wounds, scars, eczema, skin burns, skin ulcers or other skin lesions produced by psoriasis, diabetes, cancer, infections, acne or decreased circulation of blood.
  • 专利号:   EP3597594-A1, WO2020016324-A1
  • 发明人:   MARTINEZ ROVIRA M, MARTINEZ ROVIRA J A, LAVIN LOPEZ M D P, ROMERO IZQUIERDO A, RODRIGUEZ PUYOL M, RODRIGUEZ PUYOL D, DE FRUTOS GARCIA S, GRIERA MERINO M, HATEM VAQUERO M A, OROZCO AGUDO A I
  • 专利权人:   GRAPHENANO MEDICAL CARE SL, GRAPHENANO MEDICAL CARE SL
  • 国际专利分类:   A61P017/00, A61P017/02, A61P017/06, A61P017/10, A61P007/00, C01B032/18, C01B032/182, C01B032/198
  • 专利详细信息:   EP3597594-A1 22 Jan 2020 C01B-032/18 202010 Pages: 24 English
  • 申请详细信息:   EP3597594-A1 EP382531 17 Jul 2018
  • 优先权号:   EP382531

▎ 摘  要

NOVELTY - Graphene nanomaterial has a particle size distribution having a dn(90) of 0.60 mu m or smaller in number of particle and a dv(90) of 80 mu m or smaller in volume particle, as measured by laser diffraction particle analyzer, where the graphene nanomaterial is chosen from graphene nanofibers, graphene oxide or reduced graphene oxide, or their combinations. USE - The graphene nanomaterial is useful in pharmaceutical composition in form of membrane, matrix or transdermal delivery system, which is used for treating wounds, scars, eczema, skin burns, skin ulcers or other skin lesions produced by psoriasis, diabetes, cancer, infections, acne or decreased circulation of blood or preparing product from raw graphene nanofibers, graphene oxide or reduced graphene oxide (all claimed). The graphene nanomaterial is also used for treating wounds, eczema, psoriasis, scars, ulcers and other conditions. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing product from raw graphene nanofibers, graphene oxide or reduced graphene oxide, which involves (a) purifying the raw graphene material, preferably using a strong acid to remove any metal or impurity present in the graphene raw material, (b) reducing the particle size of the purified graphene nanomaterial, preferably through an exfoliation process to a particle size distribution having a dn(90) of 0.60 mu m or smaller in number of particle and a dv(90) of 80 mu m or smaller in volume particle, as measured by laser diffraction particle analyzer, and (c) subjecting the obtained product to a depyrogenization process.